OrganaBio Acquires Excellos, Expands Cell Therapy Manufacturing

OrganaBio has significantly bolstered its capabilities in the rapidly expanding cell therapy sector through the acquisition of the operating assets of Excellos. This strategic move establishes a formidable bicoastal contract testing, development, and manufacturing organization (CDMO) designed to meet the escalating demands of cell therapy developers navigating complex supply chains.

The integration of Excellos' San Diego facility, now operating under the newly formed subsidiary Excellos Labs, dramatically enhances OrganaBio's geographic reach. This expansion complements its existing East Coast hub in Miami, which offers a comprehensive suite of services including leukapheresis, birth tissue and cord blood sourcing, ISO 7 cGMP cleanroom manufacturing, process development, and quality control testing. The combined entity now boasts a network of facilities across the United States, including processing and cryopreservation labs in San Francisco and Irvine, California, alongside the newly acquired San Diego site featuring five ISO 7 cGMP cleanroom suites.

This consolidation is particularly timely given the projected growth of the cell and gene therapy market, which is anticipated to reach tens of billions of dollars in the coming years. By combining complementary expertise in manufacturing, PBMC isolation, cryopreservation, and cell processing, OrganaBio is positioning itself as a critical partner for companies developing therapies for challenging indications such as cancer and autoimmune diseases. The expanded platform is equipped to support both autologous and allogeneic cell therapies across clinical and commercial stages.

A key element of this transaction is the retention of the core Excellos team, ensuring continuity for existing client programs during the integration phase. OrganaBio CEO, Justin Irizarry, emphasized the importance of operational continuity and the combined entity's ability to match the pace and quality required by cell therapy developers and the patients awaiting these life-changing treatments. This approach aims to mitigate supply chain disruptions and provide much-needed manufacturing redundancy and geographic diversification under a unified quality management system.

The combined customer base reflects the significance of this development, encompassing many of the top 20 global pharmaceutical giants alongside emerging public and private biotechnology firms. The acquisition addresses a critical bottleneck in the cell therapy ecosystem: scalable, reliable, and geographically diverse manufacturing capacity. This move by OrganaBio is expected to accelerate the development and commercialization of novel cell-based therapeutics.

While financial terms were not disclosed, the strategic implications are clear. The full integration of both businesses is slated for completion over the next twelve months, with a focus on enhancing service offerings, improving operational efficiency, and ensuring robust support for future growth. This expansion solidifies OrganaBio's position as a leading CDMO in the highly competitive and rapidly evolving cell therapy manufacturing space.